Detailed price information for Emergent Biosolutions (EBS-N) from The Globe and Mail including charting and trades.

Press Release - A drug currently approved for smallpox in the U.S. will undergo clinical trials to treat patients infected by the Mpox viruswho are at risk of severe complications in the Democratic ...

The Africa Centre Disease Control (CDC), with global health partners, has announced the launch of a "pivotal" clinical trial ...

In a report released today, Soumit Roy from JonesTrading maintained a Buy rating on Chimerix (CMRX – Research Report), with a price ...

Emergent BioSolutions raised its revenue guidance and dropped a going concern warning. Its CEO is billing this next chapter ...

Concurrently, Emergent BioSolutions announced that brincidofovir (brand name Tembexa for smallpox treatment) will be included ...

Shares of Emergent Biosolutions climbed after the company reported an increase in revenue and swung to a profit in the third quarter. The stock was up 28% to $11.81 in Thursday afternoon trading.

Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded by George R. Painter, III and Timothy Wollaeger in April 2000 and is ...

The trial will be conducted in the Democratic Republic of the Congo in partnership with Emergent BioSolutions.

Meanwhile, COVID activity remained low amid a shift in variant proportions and RSV levels rose in 3 US regions.

Earlier today or just recently we announced our work to support a clinical trial sponsored by PANTHER and led by Africa CDC to evaluate the safety and efficacy of TEMBEXA or brincidofovir in ...